RVNC241220C2500
- 1.50
- -0.13-7.98%
Revance Therapeutics Newsroom
Revance Therapeutics Extends Tender Offer Deadline For Merger With Crown Laboratories To December 3, 2024 Amid Ongoing Discussions
Express News | Revance Therapeutics Inc - Ongoing Discussions May Result in Further Delays or Modifications to Merger Agreement
Barclays Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $7
Barclays Remains a Hold on Revance Therapeutics (RVNC)
Mizuho Securities Maintains Revance Therapeutics(RVNC.US) With Hold Rating
Cautious Hold Rating on Revance Therapeutics Amid Ongoing Merger Uncertainties With Crown Laboratories
Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday
Stifel Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $6.66
Revance Therapeutics Analyst Ratings
H.C. Wainwright Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $6.6
Revance Therapeutics Faces Strategic Uncertainty Amid Financial Shortfalls and Acquisition Challenges
Revance Therapeutics (RVNC) Gets a Hold From Needham
12 Health Care Stocks Moving In Friday's Pre-Market Session
Revance Therapeutics Reports Q3 Growth Amid Merger Plans
Revance Therapeutics Sinks Amid `going Concern' Disclosure
Express News | Revance Therapeutics: Will Not Be Providing Any Forward-Looking Guidance & Withdrawing Previously Provided Guidance & Outlook
Revance Therapeutics Q3 EPS $(0.37) Beats $(0.38) Estimate, Sales $59.88M Miss $68.20M Estimate
Revance Therapeutics | 10-Q: Q3 2024 Earnings Report
Earnings Flash (RVNC) REVANCE THERAPEUTICS Reports Q3 Revenue $59.9M
Revance Therapeutics | 8-K: Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update